5Larrey D,Geaux G P.Drug-induceda cuteil verfa ilure[J].Eur J Gastmenterol Hepatol,2005,17(2):141.
6BJORNSSON E,OLSSON R.Outcome and prognostic mark-ers in severe drug-induced liver disease[J].Hepatology,2005,42:1481-1489.
7CHALASANI N,FONTANA R J,BONKOVSKY H L,et al.Causes,clinical features,and outcomes from a prospective study of drug-induced liver injury in the United States[J].Gastroenterology,2008,135:1924-1934.
4Ott L,Mcclain CJ,Gillespie M,et al. Cytokines and meta- bolic dysfunction after severe head injury[J]. J Neuro- trauma,1994,11(5) :447-472.
5Wright G,Jalan R. Management of hepatic encephalopa- thy in patients with cirrhosis [J]. Best Pract Res Clin Gastroenterol, 2007,21 ( 1 ) : 95-110.
6Van Rossum TG, Vulto AG, De Man RA, et al. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C[J]. Aliment Pharmacol Ther, 1998,12 (3) : 199-205.
7Tandon A, Tandon BN, Bhujwala RA. Clinical spectrum of acute sporadic hepatitis E and possible benefit of gly- cyrrhizin therapy[J]. Hepatol Res,2002,23(1):55-61.
8Cheng Y,Zhang J, Shang J, et al. Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by Mag- nesium isoglycyrrhizinate in vitro [J]. Pharmacology, 2009,84(3) : 183-190.
